LEXINGTON, Mass.--(BUSINESS WIRE)--CoNCERT Pharmaceuticals Inc., the first company dedicated to creating new medicines using precision modification chemistry with the naturally-occurring element deuterium, announced today the appointment of Ronald W. Barrett, Ph.D. to its Board of Directors. Dr. Barrett is chief executive officer, co-founder and director of XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company focused on developing a portfolio of internally discovered products candidates for the potential treatment of central nervous system disorders.
